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Abstract
Drug-drug interactions (DDIs) are a common cause of adverse drug events (ADEs). The electronic 
medical record (EMR) database and the FDA's Adverse Event Reporting System (FAERS) 
database are the major data sources for mining and testing the ADE associated DDI signals. Most 
DDI data mining methods focus on pair-wise drug interactions, and methods to detect high-
dimensional DDIs in medical databases are lacking. In this paper, we propose two novel mixture 
drug-count response models for detecting high dimensional drug combinations that induce 
myopathy. The “count” indicates the number of drugs in a combination. One model is called fixed 
probability mixture drug-count response model with a maximum risk threshold (FMDRM-MRT). 
The other model is called count-dependent probability mixture drug-count response model with a 
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maximum risk threshold (CMDRM-MRT), in which the mixture probability is count-dependent. 
Compared to the previous mixture drug-count response model (MDRM) developed by our group, 
these two new models show a better likelihood in detecting high dimensional drug combinatory 
effects on myopathy. CMDRM-MRT identified and validated (54; 374; 637; 442; 131) 2-way to 6-
way drug interactions, respectively, which induce myopathy in both EMR and FAERS databases. 
We further demonstrate FAERS data capture much higher maximum myopathy risk than EMR 
data do. The consistency of two mixture models’ parameters and local false discovery rate 
estimates are evaluated through statistical simulation studies.
Keywords
Drug-count response model; Electronic medical record; FDA's Adverse Event Reporting System; 
High dimensional drug interactions; and Myopathy
1. Introduction
Adverse drug events (ADEs) are a significant cause of morbidity and mortality. ADEs lead 
to 125,000 hospital admissions each year; prolong hospital stays by nearly 1.7 to 4.6 days 
[1]; and result in as many as 4.6% of deaths in the United States [2]. It has been reported that 
26% to 59.1% of ADEs are related to DDIs [3–5]. DDIs occur due to pharmacokinetic or 
pharmacodynamic interactions between co-administrated drugs. The risk of DDI-induced 
ADEs increases exponentially with the number of drugs taken by a patient [6]. A study from 
National Center for Health statistics (NCHS) showed that the number of patients taking 
more than 3 drugs and 5 drugs has increased 1.8- and 2.5-fold in the past decade, 
respectively [7]. Therefore, the evaluation of DDIs’ clinical impact, especially for high 
dimensional drug interactions, is an important issue. Some pre-marketing clinical trials focus 
on two-way drug interactions and often are limited to specific populations, in which adverse 
drug events are usually not primary hypotheses. In addition, the clinical trial data collected 
during the premarketing phase 3 trials are typically not large enough to capture less common 
combinations of drugs. Routinely, researchers rely on pharmaco-epidemiology studies on 
large-scale health record databases to investigate drug interactions [8]. The spontaneous 
reporting system (SRS) and the electronic medical record (EMR) are two major types of 
health record data sources for post-marketing pharmacovigilance [9–12]. Recently, as these 
big health record data sets become increasingly available to the general research community, 
novel data mining algorithms have shown promise in detecting potential drug- or DDI-
induced ADEs [13–15].
Most data mining methods were developed to identify single drug induced ADEs. The 
salient examples include the information component (IC), a Bayesian confidence 
propagation neural network [16] used by World Health Organization (WHO), and the 
empirical Bayes geometric mean (EBGM) [17], which has been adopted by the United 
States Food and Drug Administration (FDA). There have been some recent developments in 
studying DDI induced ADEs. Noren et al. [18] developed a Ω shrinkage measure approach 
to screen potential pair-wise DDIs in the entire WHO database. It calculates a shrinked 
observed to expected ratio of disproportionality for a DDI induced ADE relative report rates. 
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Huang et al. [19] proposed a likelihood ratio test method (LRT) for detecting ADE signals 
from the FAERS database. Later, in order to handle the extensive zeros in the FAERS 
database, a zero-inflated Poisson model based LRT (ZIP_LRT) was proposed [20]. LRT and 
its extension can be used to detect signals for single drug (or ADE) or signals including a 
class of drugs (or ADEs) [21, 22]. Though these methods were originally developed to 
analyze the FAERS database, their extensions were derived to analyze longitudinal drug 
safety data (longitudinal LRT) as well [23]. LRT and its extensions can control the type-I 
error and false discovery rate (FDR) while retaining good power and sensitive for identifying 
signals. Thakrar et al. [24] proposed multiplicative and additive models to detect DDIs in the 
FDA’s Adverse Event Reporting System (FAERS) database. These two model assumptions 
characterize the relationship between the relative risk of the two-drug combination and the 
relative risk from two single drugs. In the DDI detecting algorithm outlined by Tatonetti et 
al. [25], they considered and adjusted the confounding variables by using propensity score 
derived from logistic regression analysis. Harpaz et al. [26] applied an association rule 
mining (ARM) to detect the multi-item ADE associations in the FAERS. In order to 
overcome the computational challenge of the ARM, Xiang et al. [27] proposed a Frequent 
Closed Item set Mining and filtering (FCI-filter) based on UMLS mapping for mining 
multiple drug interactions; and FCI-filter has been applied to FAERS data as well.
Data mining methods to detect the single drug and two-drug DDI induced ADEs cannot be 
easily expanded to evaluate high-dimensional drug interactions. In our FAERS and EMR 
database, the report frequency for most of 5-way to 6- way drug combinations is no more 
than 20. Although ARM and FCI-filter methods have the advantage of handling high-
dimensional drug and ADE combinations freely, they are indeed constructed and limited to 
ADE cases only drugs/ADEs combinations. These structural limited methods cannot easily 
be expanded to handle drug combinations whose ADE frequencies are moderate or low.
To address these challenges in detecting high-dimensional drug interactions, our group 
proposed a drug-count response model [28], where “count” indicates the number of drugs in 
a combination, and in which the same dimensionality of drug combinations shared the same 
ADE risk model. In this risk model, the same dimensionality of drug combinations either 
share the baseline risk that doesn’t depend on the dimensionality of combination drugs, or 
follows a drug-count response model that depends on the dimensionality of combination 
drugs. This model allows high-dimensional drug combinations share their ADE risks, such 
that they can borrow data strength from each other and make up the small sample size 
deficiency. Using the empirical Bayes mixture model framework, this model will give each 
drug combination a probability of belonging to a constant risk model, and a probability of 
following the drug-count response model. This drug combination specific probability allows 
us to evaluate, interpret and rank the high dimensional drug interaction evidence from the 
data. This probability also has a local discovery rate interpretation. Using the EMR data, we 
successfully identified 2- to 6-way drug combinations that increased myopathy risk at a low 
local false discovery rate [28]. However, while this model is highly powerful in detecting 
high dimensional drug interactions, it possesses intrinsic deficiencies and needs further 
improvement. Statistically, the baseline model and drug-count response model do not meet 
continuity when the number of drug equals to one. Also, the mixture probability (i.e. the 
proportion of drug combinations belonging to the drug-count response model) is fixed and 
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assumed to be the same regardless of the number of drug combinations. From the pharmaco-
vigilance point of view, the drug-count response model was tested in only one EMR 
database, and it was not externally validated. Thus, the top ranked myopathy associated 
high-dimensional drug interactions identified by the method were not yet validated. In this 
paper, our novel mixture drug-count response models address these statistical and 
pharmacology challenges. In order to identify which drug combination follows the drug-
count response model or constant risk model, we use both EMR and FAERS datasets to 
derive their drug-count response models, and evaluate and validate top myopathy associated 
high-dimensional drug interactions.
2. Methods
2.1 Data Sources
The data sources used in this analysis are the FDA’s Adverse Event Reporting System 
(FAERS) and the Indiana Network of Patient Care data, which is an Electronic Medical 
Record (EMR) database.
2.1.1 FAERS Data Set—FAERS contains spontaneous adverse drug event reports from 
healthcare professionals, consumers, and pharmaceutical manufactures. The data used in this 
paper were from the FAERS 2004Q1 to 2012Q3. Duplicated reports that had the same 
primary record ID were removed. ADEs in the FAERS were annotated using MedDRA’s PT 
code [29]. The drug names in the FAERS may contain abbreviations, brand names, 
synonyms, and sometimes contain spell mistakes. Therefore, they were normalized through 
a drug name mapping scheme implemented in the DrugBank. Un-mapable names due to 
spelling errors (i.e. drug names that are only one letter different from a generic name, a 
brand name, or a synonym) and with the reporting frequency greater than 1000 were 
manually checked and mapped. After data clean-up, the FAERS dataset contained 4,280,322 
reports with 1,753 generic drug names and 15,445 MedDRA PT ADE names.
2.1.2 Indiana Network of Patient Care Data Set—Indiana Network for Patient Care 
(INPC) is a local health information infrastructure that has been approved as exempt 
research by institutional review board (IRB) [30]. A subset of INPC called Common Data 
Model (CDM) are de-identified and extracted. This data set contains coded prescription 
medications, diagnoses, and lab tests for 2.2 million patients between 2004 and 2009. The 
CDM data have been processed with the Observational Medical Outcomes Partnership 
Common Data Model [31].
2.2 Case and Control Definitions
2.2.1 Myopathy Case and Control Definitions in FAERS—From 4,280,322 reports 
in the FAERS dataset, we defined myopathy “cases” as those reports listing myositis, 
myoglobinuria, muscle fatigue, muscle spasms, myalgia, muscle injury, muscular weakness, 
polymyositis and rhabdomyolysis (Table S1). All other reports that do not contain these 
ADEs are defined as controls. Based on this definition, we identified 140,071 cases and 
4,140,251 controls in the FAERS database.
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2.2.2 Myopathy Case and Control Definitions in INPC—The myopathy cases (Table 
S1) in the INPC are similar to the myopathy cases defined in the FAERS.
For the EMR database, we defined two types of myopathy events: 1) the first event of 
myopathy that occurs more than 6 months after the start of the database (01/01/2004), and 2) 
any additional myopathy event(s) that occur(s) more than 6 months after the previous 
myopathy event. In another word, for patients with multiple myopathy events, a 6-month 
myopathy free window was used for selecting any additional myopathy event(s).
Patients who experienced a myopathy event are considered cases. For each case, a drug 
exposure window is set as 1 month prior to the index event, and the drug(s) prescribed 
during this time period are classified as being associated with myopathy. For the control 
group, we randomly selected 50 patients who did not experience a myopathy event during 
the same time interval as the case. Drugs prescribed to these patients during the one month 
period before the index date are classified as not being associated with myopathy [32, 33].
2.3 Drug and Drug Combination Selections
For this analysis, we limited the number of drugs studied to the 20 most frequent drugs 
associated with myopathy in the EMR dataset (Table S2) [28]. Among these 20 drugs, 17 are 
associated with myopathy (the myopathy definition are shown in the Table S1) side effect in 
the Side Effect Resource database [34].
For the 20 drugs, we selected all their possible 2-way to 6-way drug combinations in EMR 
and FAERS resulting in 60,460 possible drug combinations. To avoid false positive signals, 
both the FAERS and EMR datasets were filtered so that only those drug combinations with a 
total report number (case number plus control number) greater than 4 (nij > 4) were 
evaluated. This filtering step reduced the number of drug combinations in the EMR to 
20,161 and FAERS to 31,476 combinations (Figure S1).
2.4 Mixture Drug-Count Response Models
2.4.1. Previously Defined Drug-Count Response Model—Our group has previously 
described a mixture drug-count response model (MDRM) [28] for identifying myopathy 
induced by high-dimensional drug interactions. In this model, “count” indicates the number 
of drug combinations. The primary novelty of this model was a mixture of two model 
components: one component represents a constant myopathy risk regardless of the 
dimensionality of drug combinations while the other component characterizes an increasing 
drug-count response relationship between the dimensionality of drug combinations and the 
myopathy risk.
In the mixture drug-count response model, i indicates the number of drugs for i-way drug 
combinations; j is the jth i-way drug combinations; Nij is the total number of patients taking 
jth i-way drug combination; and Yij is the number of cases among those Nij patients. 
Additionally, let Zij be the underlying binary random variable. Specifically, if Yij follows the 
drug-count response model, Zij equals to 1; otherwise Zij equals to 0 when Yij follows the 
constant model. The joint distribution of (Yij, Zij) is
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(1)
Where π is the proportion of drug combinations that follow the drug-count response 
component;  represents the constant ADE risk; and 
represents the drug-count response ADE risk. Then, the marginal distribution of Yij can be 
written as a two-component mixture distribution (2):
(2)
2.4.2 Novel Mixture Drug-Count Response Models—Here, we propose two novel 
drug-count response models to identify the myopathy risk induced by high-dimensional drug 
combinations: a fixed probability mixture drug-count response model with a maximum risk 
threshold (FMDRM-MRT) model, and a count-dependent probability mixture drug-count 
response model with a maximum risk threshold (CMDRM-MRT) model. As in our previous 
model, “count” indicates the number of drug combinations.
Fixed Probability Mixture Drug-Count Response Model with a Maximum Risk 
Threshold (FMDRM-MRT): In the FMDRM-MRT, the definitions of i (1<i<6) and j; the 
random variables, Nij, Yij and Zij; and the parameter π are the same as in the MDRM. We 
also assume that the marginal distribution function of Yij follows a two-component mixture 
distribution (same as equation 1). However, in the FMDRM-MRT model q0 and q1 are 
defined as:  and .
The FMDRM-MRT has two noticeable differences from the MDRM. First, the β1(i − 1) is 
revised on the β1i in the MDRM, when i = 1, q0 and q1 are equal. This follows a continuity 
assumption. Second the maximum ADE risk of FMDRM-MRT is bounded by c, while the 
maximum risk of MDRM is 1.
Under FMDRM-MRT, the joint distribution function of (Yij, Zij) can be written as
(3)
The marginal distribution function of Yij is
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(4)
The log-likelihood function based on (4) is
(5)
Count-dependent Probability Mixture Drug-Count Response Model with a Maximum 
Risk Threshold (CMDRM-MRT): In this model, we assume that the proportion of drug 
combinations following the drug-count response model will depend on the dimensionality of 
drug combinations. Therefore, the joint distribution function of (Yij, Zij) changes to (6).
(6)
where πi (i = 1,2, …, 6 and 0 < πi < 1) is the proportion of i-way drug combinations that 
follow the drug-count response component. The marginal distribution function for (6) is
(7)
The log-likelihood function for (7) can be written as
(8)
2.5 Expectation-Maximization Algorithm
As Zij is not observed, the maximum likelihood estimators (MLEs) of parameters in 
equations (3) and (6) can be obtained through an expectation-maximization (EM) algorithm. 
Hence, we define l(nij, yij, zij; θ) = ΣiΣj log P(yij, zij) as the log-likelihood for equations (3) 
and (6). The EM algorithm is an iterative method and after the tth iteration, θt is the 
estimator of θ. First, in the E-step, Q(nij, yij, wij; θ) = EZ|Y[l(nij, yij, zij; θ)|yij, θt] is 
computed, and wij is the estimator of Zij.
For CMDRM-MRT, the wij can be written as
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(9)
Correspondingly, for DMDRM-MRT wij is
(10)
Second, we find θt+1 in the M-step, where .
In this study, the maximization is carried out by using the R function nlminb, which is an 
unconstrained and box-constrained optimization using PORT routines which is a Newton-
like method.[35]
2.6 Local False Discovery Rate
The local false discovery rate (lfdr) was introduced by Efron et al. [36] for analyzing data 
from microarray experiments, and was defined as the posterior probability of a gene’s 
expression belonging to “null distribution” [37]. In both FMDRM-MRT and CMDRM-MRT, 
drug combinations have either a constant myopathy risk (“null distribution”) or a drug-count 
response risk. Thus, both models follow the same model framework of Efron et al. [37]. The 
lfdrs for FMDRM-MRT and CMDRM-MRT are defined in (11) and (12), respectively:
(11)
(12)
lfdrs in (11) and (12) represent the posterior probabilities that a drug combination has a 
constant myopathy risk; i.e. lfdr represents the odds that myopathy risk will be constant as 
the dimensionality of drug combination increases.
2.7 Likelihood Ratio Test
Because FMDRM-MRT and CMDRM-MRT are nested models, the likelihood-ratio test is 
used to test and compare the goodness of fit between two models. Let the FMDRM-MRT be 
considered the null model, and the CMDRM-MRT be the alternative model. The likelihood 
ratio can then be defined as
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(13)
According to Wilks’ theorem [38], the test statistic −2log(Λ) can be assumed to follow a chi-
squared distribution. Our model has 4 degrees of freedom.
(14)
2.8 Simulation Study
To evaluate the performance of our models, a simulation study was conducted to assess local 
false discovery rate estimates. In the simulation, λi is the mean of Nij in i-way drug 
combinations, and ki is the number of i-way drug combinations in the simulation. Nij is the 
number of patients taking the jth i-way drug combinations and it follows a Poisson 
distribution with the mean equals to λi. Yij is the number of drug combinations with 
myopathy cases in Nij. Let Zij be the random binary variable. Specifically, Zij = 1 if Yij 
follows a drug-count response myopathy risk, otherwise Zij = 0 when Yij has a constant 
myopathy risk. Zij is generated using a Bernoulli distribution with a probability πi. Given 
Nij, we assume Yij follows a binomial distribution with size Nij and probability equal to q0 
or q1, it depends on the value of Zij, either follows the drug-count response myopathy risk or 
the constant myopathy risk.
In order to assess the consistency of the lfdr estimate, we calculate the model based 
estimate and the empirical lfdrij estimate in the simulation study. The simulation data {nij, 
yij, zij, }, are divided into 100 intervals according to the value of nij and yij/nij. In each 
interval, we calculate the model based lfdr which is defined as the mean of  and the 
empirical lfdr which is the proportion of zij = 0.
3. Results
3.1 Model Performance Comparisons among CMDRM-MRT, FMDRM-MRT and MDRM
All three models are fitted to the EMR dataset and FAERS dataset. Their parameter 
estimates are shown in Table I. In fitting the EMR data, CMDRM-MRT shows an increasing 
trend of probability, i.e. from π1 to π6, (0.50, 0.67, 0.73, 0.82, 0.90, 0.94) respectively, that 
drug combinations follow drug-count response model (Figure 1). The likelihood ratio test 
between CMDRM-MRT to FMDRM-MRT has a p-value of 8.3 × 10−35 suggesting that 
CMDRM-MRT fit the data better than FMDRM-MRT. This is a piece of strong evidence 
that the mixture probability of drug-count response model is indeed drug-count dependent. 
Both CMDRM-MRT and FMDRM-MRT models show comparable maximum myopathy 
risk, 0.448 vs 0.460 (Table I, Figure 1 and 2), respectively. On the other hand, MDRM 
shows a relatively higher mixture probability of drug-count response compared to the other 
models. This is likely because the MDRM allows a discontinuous drug-count response 
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model and the constant risk model for the single drug, and drug-count response model has a 
higher myopathy risk than the constant risk model (Figure 3).
In fitting the FAERS data, CMDRM-MRT also shows an increasing trend of probability of 
drug-count response model when the drug combination goes from 1 to 3, i.e. (0.50, 0.53, 
0.78) respectively, and this probability stabilizes around 0.80 when the drug combination 
goes from 4 to 6 (Figure 1). The likelihood ratio test between CMDRM-MRT to FMDRM-
MRT has a p-value of 1.9 × 10−6, suggesting that CMDRM-MRT fits the data better than 
FMDRM-MRT does. The mixture probability of drug-count response model thus appears 
drug-count dependent in FAERS. Comparing CMDRM-MRT to FMDRM-MRT, both 
models show the same maximum myopathy risk, 0.999 (Table I, Figure 1 and 2). However, 
MDRM shows lower mixture probability of drug-count response model than the other 
models. Because the MDRM allows a discontinuous drug-count response model and the 
constant risk model for the single drug, the drug-count response model has a lower 
myopathy risk than the constant risk model. (Figure 3).
Comparing CMDRM-MRT’s fitting and performance between FAERS and EMR data sets 
(Figure 1), FAERS’s drug-count response model shows a much steeper increase of 
myopathy risk than EMR’s drug-count response model does. FAERS has a much higher 
maximum myopathy risk, 0.999 than the EMR has (i.e. 0.448) when drug count goes high. 
Similarly, both EMR and FAERS have the similar increasing trend of mixture probability of 
drug count response model.
3.2 Common Myopathy Associated Drug Combinations Identified from EMR and FAERS 
Data Sets
Using an lfdr threshold of 0.00001, significant drug combinations are selected from both 
EMR and FAERS data sets. Figure 4 displays the overlapped drug combinations with 
lfdr<0.00001 (red dots) and lfdr>0.00001 (black dots) between two data sets. CMDRM-
MRT and FMDRM-MRT have very similar pattern, while MDRM shows different trend. As 
shown in Figure 5, MDRM identifies more two-way drug combinations than the other two 
models, but fewer high-dimensional drug combinations (3-way to 5-way). This is mainly 
because of the mis-specified discontinuity assumption between drug-count response model 
and constant risk model in the MDRM.
3.3 Common Myopathy Associated 6-Way Drug Combinations
Using the CMDRM-MRT model, 131 six-way drug combinations were identified in both the 
FAERS and EMR databases with lfdr < 0.00001. The FMDRM-MRT model yielded 97 six-
way drug combinations with lfdr < 0.00001. Table II presents several examples of the 6-way 
drug combinations detected by CMDRM-MRT model that were associated with increased 
myopathy risk in both the FAERS and EMR databases. Myopathy risk associated with these 
combinations ranged from 0.38 to 0.73 in the EMR and 0.43 to 0.76 in the FAERS analyses. 
Only one of the 14 drugs that are presented in these 6-way drug combinations have not been 
shown to have myopathy risk in the SIDER database [34]. Of note, three of these 6-way 
combinations include simvastatin or atorvastatin and drugs known to inhibit their 
metabolism. These combinations can lead to increased exposure of the statin drugs, which 
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are commonly known to cause myopathy. Considering the baseline risk estimated from the 
constant risk model in CMDRM-MRT, these 6-way drug combinations have 3.45- to 10.85-
fold increase in myopathy risk.
3.4 Assess lfdr Estimate through A Simulation Study
The CMDRM-MRT was further evaluated in a simulation study. Parameter values were 
selected using estimates from the FAERS data analysis. In the simulation, 15 drugs were 
used to generate the drug combinations, resulting in 105 2-way combinations; 455 3-way 
combinations; 1,365 4-way combinations; 3,003 5-way combinations, and 5,005 6-way 
combinations. 500 simulated data sets were generated. Each time, the EM algorithm was 
used to estimate the parameters in the CMDRM-MRT. Table III presents the model-based 
estimates, their SDs, 95% CI, SD/estimates and relative biases. The relative biases of these 
estimates ranged from 0 to 1%. The SDs estimated from the simulations are also very small 
compared to the estimates, suggesting a high confidence on these parameter estimates. 
Figure 6 further demonstrates the consistency of the model based lfdr estimate (y-axis) and 
empirical lfdr estimate (x-axis) estimated from the simulation data.
4. Discussion
In this article, we propose two novel mixture drug-count response models, FMDRM-MRT 
and CMDRM-MRT to characterize relationship between the counts of drug combinations 
and the myopathy risks. Unlike MDRM [28], these two models speculate the maximum 
myopathy risk as one model parameter, and allow drug-count response model and constant 
risk model share the same myopathy risk when drug count is 1. In addition, CMDRM-MRT 
further allows the mixture probability to be drug count dependent. Using EMR and FAERS 
datasets, we demonstrate that CMDRM-MRT fits data better than FMDRM-MRT, p =8.3 × 
10−35 and 1.9 × 10−6, respectively. Interestedly, both CMDRM-MRT and FMDRM-MRT 
suggest that maximum myopathy risk reaches to 0.999 in FAERS and 0.45 in EMR when the 
drug counts in drug combinations goes high. This difference of maximum myopathy risk 
between two databases make sense, because FAERS is designed to capture the adverse drug 
events, while EMR keeps tracks all the medical info for patients. Nevertheless, these 
maximum myopathy risk estimates are strikingly high, comparing to the background 
myopathy risk estimated from the constant risk model (q0), which are 0.11 and 0.07 in EMR 
and FAERS, respectively.
Due to the accuracy of the high dimensional drug interactions that detected by our models 
can be improved by combining the FAERS database and EMR database [39], all the 
myopathy associated 2-way to 6-way drug interactions are validated between two databases. 
Based on an lfdr threshold of 0.00001, we further select six 6-way drug combinations among 
atorvastatin, simvastatin, ondansetron, escitalopram, omeprazole, venlafaxine, zolpidem, 
promethazine, acetaminophen, hydrocodone, alprazolam, oxycodone, duloxetine, tramadol. 
Among these drugs, only ondansetron does not have myopathy side effect in SIDER 
database [34]. It should also be noted that a number of the drugs identified in our six-way 
drug combinations may also be used to treat pain associated with myopathy (e.g. 
acetaminophen, hydrocodone, oxycodone, tramadol). Since the FAERS database does not 
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distinguish between drugs taken prior to the diagnosis of myopathy and those taken after the 
diagnosis of myopathy, we do not know whether these drugs lead to the myopathy event or if 
they were given as treatment for the event. However, the EMR database is capable of 
separating drugs prescribed before the myopathy event from those administered as treatment 
for myopathy. As this data set also supports the correlation between pain relievers and 
myopathy, the co-administration of these drugs is likely to be associated with increased risk 
of myopathy. Considering their 6-way drug interaction induced myopathy risk ranging from 
0.38 to 0.76 in two databases, it is essential to recognize that these risks are 3.45 to 10.85 
fold higher than the background risk. Therefore, for the first time, in population level (i.e. 
considering all the drug combinations) and individual level (i.e. drug combination specific), 
our newly proposed drug-count response models characterize and select the high 
dimensional drug interactions and estimate their myopathy risks. Our follow-up simulation 
studies further show the consistency of parameters and lfdr estimates.
FMDRM-MRT and CMDRM-MRT, however, have not been able to incorporate the other 
confounding variables in the current mixture model framework. Therefore, the interpretation 
of the data needs to be cautious before it can be done. As the number of drug combinations 
will increase exponentially as the number of drug rise, computation is another limiting factor 
that we right now can not apply our models to all 1000 plus drugs in EMR and FAERS 
databases. Another interesting issue is that some patients take extreme high number of co-
medications. For examples, we have observed patients who took >90 drugs in the FAERS 
database. Each of these patients will contribution a great number of drug combinations, and 
the usage of this patient data will be tremendously out-weight some drug combinations that 
are only taken by a few patients. This issue needs to be further addressed more carefully and 
systemically in the future.
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Figure 1. 
The CMDRM-MRT fit myopathy risks, distribution of the proportion of drug combinations 
that follow the drug-count response component (πi) and the number of drug combinations in 
the EMR and FAERS datasets.
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Figure 2. 
The FMDRM-MRT fit myopathy risks in the EMR and FAERS datasets.
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Figure 3. 
The MDRD fit myopathy risks in the EMR and FAERS datasets.
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Figure 4. 
The distribution of −log10 (lfdr) for the 2 way to 6 way common drug combinations in the 
EMR and FAERS datasets. The purple line is a threshold with −log10 (lfdr) =5 (lfdr 
=0.00001), red plot means the common drug combinations with the condition of −log10 
(lfdr) > 5 (lfdr <0.00001) in two datasets.
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Figure 5. 
Statistic the number of common drug combinations for 2 way to 6 way drug combinations in 
the EMR and FAERS dataset with the condition of lfdr<0.00001 for the three models, 
respectively.
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Figure 6. 
Comparison of the model based lfdr and the empirical lfdr.
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Table I
Parameters estimated for CMDRM-MRT, FMDRM-MRT and MDRM using EMR and FAERS dataset. {π1, 
π2, π3, π4, π5, π6} are the proportions of 2 way to 6 way drug combinations that follow drug-count response 
component. c is the maximum Myopathy risk.
a.
Dataset EMR
Parameter CMDRM-MRT [95%CI] FMDRM-MRT [95% CI] MDRM [95% CI]
π1 - 0.869 [0.858, 0.880] 0.929 [0.920, 0.939]
π2 0.667 [0.564, 0.770] 0.869 [0.858, 0.880] 0.929 [0.920, 0.939]
π3 0.726 [0.683, 0.768] 0.869 [0.858, 0.880] 0.929 [0.920, 0.939]
π4 0.823 [0.801, 0.845] 0.869 [0.858, 0.880] 0.929 [0.920, 0.939]
π5 0.904 [0.890, 0.919] 0.869 [0.858, 0.880] 0.929 [0.920, 0.939]
π6 0.937 [0.920, 0.952] 0.869 [0.858, 0.880] 0.929 [0.920, 0.939]
c 0.448 [0.441, 0.456] 0.460 [0.443, 0.478] -
β0 −1.084 [−1.107, −1.060] −1.120 [−1.168, −1.072] −2.269 [−2.284, −2.254]
β1 0.843 [0.820, 0.866] 0.810 [0.767, 0.853] −1.908 [−1.926, −1.889]
β2 - - 0.304 [0.298, 0.309]
b.
Dataset FAERS
Parameter CMDRM-MRT [95% CI] FMDRM-MRT [95% CI] MDRM [95% CI]
π1 - 0.798 [0.791, 0.805] 0.675 [0.667, 0.684]
π2 0.532 [0.423, 0.641] 0.798 [0.791, 0.805] 0.675 [0.667, 0.684]
π3 0.781 [0.742, 0.821] 0.798 [0.791, 0.805] 0.675 [0.667, 0.684]
π4 0.808 [0.788, 0.827] 0.798 [0.791, 0.805] 0.675 [0.667, 0.684]
π5 0.790 [0.778, 0.803] 0.798 [0.791, 0.805] 0.675 [0.667, 0.684]
π6 0.803 [0.793, 0.813] 0.798 [0.791, 0.805] 0.675 [0.667, 0.684]
c 0.999 [0.989, 1.000] 0.999 [0.991, 1.000] -
β0 −2.554 [−2.567, −2.541] −2.562 [−2.579, −2.546] −1.594 [−1.605, −1.583]
β1 0.695 [0.691, 0.699] 0.697 [0.693, 0.700] −3.874 [−3.886, −3.862]
β2 - - 0.881 [0.877, 0.884]
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